Montreal Heart Institute
Montreal, Quebec, H1T1C8, Canada
NCT Number: NCT06637293
The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence.
The primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H1T1C8, Canada
Mathematically, sensitivity is calculated as True Positive / (True Positive + False Negative), where True Positive represents correctly referred patients and false negatives represents patients who should have been referred but were not.
The secondary objectives include determining the rate of cardiovascular evaluation referrals before and after the intervention (implementation of the DeepECG platform), the individual characteristics of the intervention (PPV, NPV, and specificity), as well as evaluating the feasibility of implementing AI-based automatic ECG interpretation in primary care through surveys of family physicians and cardiologists.
PPV: Positive predictive value NPV: Negative predictive value
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Family Physicians or Nurse Practitioners
Family physicians or nurse practitioners (NPs) practicing in one of the participating FMGs.
Family physicians who have given their free and informed consent. Patients
Adult patients (18 years or older). Patients without follow-up in cardiology or internal medicine for cardiovascular issues (arrhythmia, heart failure, myocardial infarction, atherosclerotic coronary artery disease, valvular heart disease) or those who had a negative investigation in the past with no additional follow-up.
ECG
Any 12-lead ECG performed with the MUSE GE 360 machine. ECG of adequate technical quality for interpretation (otherwise, it will be automatically rejected by the platform).
-
Exclusion criteria
Family physicians practicing exclusively in pediatrics (patients under 18 years old).
Family physicians unable to follow the project guidelines.
EchoNeXT& ECG-AI algorithm
Time frame: 18 months
Compare the sensitivity of cardiology referrals made by family physicians and nurse practitioners before and after the activation of AI-assisted diagnostics and recommendations from the DeepECG platform.
Time frame: 18 months
Compare the specificity, negative predictive value, and positive predictive value of cardiology referrals made by family physicians and nurse practitioners before and after the activation of AI-assisted diagnostics and recommendations.
Contact information is provided by the study sponsor or research team.
Montreal Heart Institute
Other
Acronym: DAISEA-ECG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06904469
Primary Care Provider
Vaasa, Finland
View Trial DetailsNCT00119041
Autoimmune Diseases, Diabetes Mellitus
Ann Arbor, Michigan, United States
View Trial DetailsNCT05372627
Cardiovascular Diseases, Heart Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07296016
Cardiovascular Diseases, Heart Diseases
Hong Kong, Shatin
View Trial Details